Every material Form 8-K TG Therapeutics has filed with the SEC since November 01, 2023, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
TG Therapeutics reported second quarter 2026 total revenue of $240.3 million, up from $141.1 million a year earlier, and raised its full-year 2026 total global revenue target to approximately $950 million. Net income fell to $7.8 million from $28.2 million as research and development and selling, general and administrative expenses rose sharply, so higher sales did not translate into higher profit.
Q2 2026 total revenue was $240.3 million, versus $141.1 million in Q2 2025; BRIUMVI U.S. net product revenue was $227.7 million.
Q2 2026 net income was $7.8 million ($0.05 diluted per share), versus $28.2 million ($0.17 diluted per share) in Q2 2025.
Q2 2026 R&D expense was $95.3 million and SG&A expense was $82.1 million, versus $31.8 million and $55.6 million a year earlier.
Full-year 2026 targets were raised: total global revenue to approximately $950 million and BRIUMVI U.S. net product revenue to approximately $890 to $905 million.
TG Therapeutics reported first quarter 2026 total revenue of $204.9 million, up from $120.9 million a year earlier, and net income of $19.8 million, up from $5.1 million. The company raised its full-year 2026 total global revenue target to approximately $925 million and its BRIUMVI U.S. net product revenue target to $885-900 million, from $825-850 million.
Total revenue was $204.9 million versus $120.9 million for Q1 2025; BRIUMVI U.S. net product revenue was $194.8 million, about 63% higher year over year.
Net income was $19.8 million, with diluted EPS of $0.12 versus $0.03 in Q1 2025.
SG&A expense rose to $88.2 million from $50.3 million, and R&D expense was $48.4 million versus $46.4 million.
Second quarter 2026 BRIUMVI U.S. net product revenue target is approximately $220 million.
TG Therapeutics entered a first amendment to its financing agreement on March 18, 2026, establishing a $750 million term loan maturing March 18, 2031, fully borrowed at closing, with part of the proceeds used to repay the existing Initial Term Loans in full. The filing also sets up an uncommitted additional facility of up to $250 million, and the loan is secured by substantially all assets of the company and its guarantor subsidiaries.
$750 million 2026 Term Loan borrowed in full on March 18, 2026, with proceeds partly used to repay Initial Term Loans
Loan matures March 18, 2031; quarterly amortization of $37.5 million begins with the quarter ending March 31, 2030
Pricing grid starts at 4.75% for SOFR borrowings and 3.75% for base rate borrowings, with a 25 basis point step-down tied to leverage
Uncommitted additional facility of up to $250 million; Blue Owl Capital Corporation is administrative agent
TG Therapeutics reported fourth-quarter and full-year 2025 results, with total revenue of $192.6 million for the quarter and $616.3 million for the year, driven by BRIUMVI sales. Fourth-quarter net income was $23.0 million, slightly below the prior-year quarter, while full-year net income of $447.2 million includes a non-recurring income tax benefit of approximately $339.8 million. The company set a 2026 target of approximately $875-$900 million in total global revenue.
Q4 2025 total revenue was $192.6 million, versus $108.2 million in Q4 2024; full-year 2025 total revenue was $616.3 million, versus $329.0 million in 2024.
Q4 2025 net income was $23.0 million, versus $23.3 million in Q4 2024; full-year 2025 net income of $447.2 million includes a tax benefit of approximately $339.8 million.
2026 targets: total global revenue of approximately $875-$900 million and BRIUMVI U.S. net product revenue of approximately $825-$850 million.
Cash, cash equivalents and investment securities were $199.5 million as of December 31, 2025; a new share repurchase program of up to $100 million was announced.
TG Therapeutics reported third quarter 2025 total revenue of $161.7 million, up from $83.9 million a year earlier, and net income of $390.9 million, which includes a non-recurring income tax benefit of approximately $365.0 million. The company raised its full-year 2025 BRIUMVI U.S. net product revenue target to approximately $585 million and its global revenue target to approximately $600 million, and authorized a new $100 million share repurchase program.
Q3 2025 total revenue of $161.7 million, including BRIUMVI U.S. net revenue of $152.9 million, versus $83.9 million total revenue in Q3 2024
Net income of $390.9 million, including a non-recurring income tax benefit of approximately $365.0 million; operating income was $29.4 million
Full-year 2025 BRIUMVI U.S. net product revenue target raised to approximately $585 million from $570-$575 million; global revenue target raised to approximately $600 million from $585 million
Completed the prior $100 million share repurchase, buying about 3.5 million shares at an average $28.55; new $100 million program authorized
TG Therapeutics reported second quarter 2025 total revenue of $141.1 million, up from $73.5 million a year earlier, and net income of $28.2 million, compared with $6.9 million. The company raised its full-year 2025 BRIUMVI U.S. net revenue target to $570 million to $575 million from $560 million, and its total global revenue target to approximately $585 million from $575 million.
Q2 2025 BRIUMVI U.S. net product revenue was $138.8 million, up 91% from the same period last year.
Full-year 2025 BRIUMVI U.S. net revenue target raised to $570 million to $575 million, from $560 million.
Full-year 2025 total global revenue target raised to approximately $585 million, from $575 million.
Cash, cash equivalents and investment securities were $278.9 million as of June 30, 2025.
TG Therapeutics reported first quarter 2025 total revenue of $120.9 million, up from $63.5 million a year earlier, and net income of $5.1 million compared with a net loss of $10.7 million. The company raised its full-year 2025 BRIUMVI U.S. net product revenue target to $560 million and its global revenue target to $575 million.
Total revenue of $120.9 million for the three months ended March 31, 2025, versus $63.5 million a year earlier
Net income of $5.1 million, or $0.03 per diluted share, versus a net loss of $10.7 million in the prior-year quarter
Full-year 2025 BRIUMVI U.S. net product revenue target raised to $560 million from $525 million; global revenue target raised to $575 million from $540 million
Total research and development expense rose to $46.4 million and selling, general and administrative expense to $50.3 million
TG Therapeutics reported fourth-quarter and full-year 2024 results, with full-year total revenue of $329.0 million and net income of $23.4 million, compared with $233.7 million and $12.7 million in 2023. The company set a 2025 target of approximately $540 million in total global revenue and said its $311.0 million in cash, cash equivalents and investment securities, combined with projected BRIUMVI revenue, should fund the business under its current operating plan.
Q4 2024 total revenue was $108.2 million, compared with $44.0 million in Q4 2023; Q4 2024 net income was $23.3 million, compared with a net loss of $14.4 million.
Full-year 2024 total revenue was $329.0 million, compared with $233.7 million in 2023; 2023 included recognition of a one-time $140.0 million Neuraxpharm upfront payment.
2025 target total global revenue is approximately $540 million, including BRIUMVI U.S. net product revenue of approximately $525 million.
Cash, cash equivalents and investment securities were $311.0 million as of December 31, 2024.
TG Therapeutics reported third quarter 2024 results and raised its full-year 2024 U.S. BRIUMVI net product revenue target to $300 million to $305 million, up from $290 million to $300 million. Product sales are growing quickly, but total revenue and net income fell sharply from the prior-year period, which included a large license payment.
Q3 2024 U.S. BRIUMVI net product revenue was $83.3 million, about 15% above the prior quarter and over 230% above Q3 2023.
Full-year 2024 U.S. BRIUMVI net revenue target raised to $300 million to $305 million from $290 million to $300 million.
Q3 2024 net income was $3.9 million, compared with $113.9 million in Q3 2023, which included license revenue of $140.7 million.
Cash, cash equivalents and investment securities were $341.0 million as of September 30, 2024.
TG Therapeutics reported second-quarter 2024 total revenue of $73.5 million, up from $16.1 million a year earlier, and net income of $6.9 million compared with a net loss of $47.6 million in the same period of 2023. The company raised its full-year 2024 U.S. BRIUMVI net revenue target to $290 million to $300 million from $270 million to $290 million, and authorized a share buyback of up to $100 million funded by a new $250 million term loan that repaid its Hercules debt.
Q2 2024 total revenue was $73.5 million versus $16.1 million in Q2 2023; diluted EPS was $0.04 versus $(0.34).
Full-year 2024 U.S. BRIUMVI net revenue target raised to $290 million to $300 million from $270 million to $290 million.
$250 million term loan with Blue Owl Capital and HealthCare Royalty matures August 2, 2029; proceeds repaid Hercules debt, and the Board authorized up to $100 million in share repurchases.
Audit Committee concluded a 2021 stock-grant expense error reflects a material weakness in internal control as of December 31, 2023; a 10-K/A will follow, and the company states there are no financial changes to the 2023 annual report.
At its June 14, 2024 annual meeting, TG Therapeutics stockholders approved raising authorized common stock from 175,000,000 to 190,000,000 shares and removing the full-value awards limit in the 2022 Incentive Plan. The company filed the charter amendment the same day, and all five proposals passed, although three director nominees received less than half of the votes cast for them. The larger share authorization gives the company room to issue more common stock, which could dilute existing holders.
Authorized common shares rise from 175,000,000 to 190,000,000; 73,780,225 votes for, 36,348,764 against, 946,040 abstentions.
2022 Incentive Plan amendment removing the full-value awards limit passed with 66,744,142 votes for and 8,625,685 against.
Advisory say-on-pay vote: 42,346,581 for, 31,019,084 against, 2,748,761 abstentions.
Yann Echelard (46.05%), Daniel Hume (46.03%) and Sagar Lonial, MD (43.75%) each received less than half of votes cast for them.
TG Therapeutics reported first quarter 2024 total revenue of $63.5 million, up from $7.8 million a year earlier, and a net loss of $10.7 million, down from $39.2 million. The company raised its full-year 2024 U.S. BRIUMVI net product revenue target to $270 million to $290 million, from $220 million to $260 million previously.
Q1 2024 total revenue of $63.5 million, including a $12.5 million milestone payment tied to the first EU launch of BRIUMVI in Germany
Q1 2024 U.S. BRIUMVI net product revenue of $50.5 million; company targets approximately $65 million for Q2 2024
Net loss of $10.7 million, or $0.07 per share, versus $39.2 million, or $0.28 per share, in Q1 2023
Cash, cash equivalents and investment securities of $209.8 million as of March 31, 2024
TG Therapeutics reported fourth quarter and full year 2023 results, furnished as Exhibit 99.1 to a Form 8-K. Full-year total revenue was $233.7 million, including a $140.0 million one-time payment from Neuraxpharm, and the company swung to net income of $12.7 million from a $198.3 million net loss in 2022. The company also set a 2024 BRIUMVI U.S. net product revenue target of $220 million to $260 million, giving shareholders a benchmark for future results.
Q4 2023 total revenue was $44.0 million versus $80 thousand in Q4 2022; Q4 net loss narrowed to $14.4 million from $53.0 million.
Full-year 2023 BRIUMVI U.S. net product revenue was $88.8 million; license, milestone and other revenue was $141.7 million, mainly from the $140.0 million Neuraxpharm payment received in July 2023.
2024 targets: BRIUMVI U.S. net product revenue of approximately $220 million to $260 million and total operating expense of approximately $250 million.
Year-end 2023 cash, cash equivalents and investment securities were $217.5 million.
TG Therapeutics preliminarily reported unaudited U.S. BRIUMVI net product revenue of approximately $40 million for the fourth quarter of 2023 and $89 million for the full year, with a year-end 2023 cash position of approximately $215 million. It also set 2024 targets of $220 million to $260 million in full-year BRIUMVI revenue and about $250 million in operating expense, and disclosed a January 7, 2024 license for azer-cel from Precision BioSciences. The filing does not give prior-period comparisons, so the figures alone do not show whether results improved.
Preliminary U.S. BRIUMVI net product revenue of approximately $40 million for Q4 2023 and $89 million for full year 2023, unaudited
2024 targets: $41 million to $46 million for Q1 BRIUMVI revenue and $220 million to $260 million for full year; full-year operating expense of approximately $250 million
Azer-cel license with Precision BioSciences dated January 7, 2024: $7.5 million upfront and up to $288 million in additional milestone payments, plus royalties
TG Therapeutics reported results for the third quarter ended September 30, 2023, with total revenue of $165.8 million, of which $140.0 million was a one-time payment from Neuraxpharm. The company reported net income of $113.9 million, compared with a net loss of $35.8 million a year earlier, and said cash, cash equivalents and investment securities were $229.2 million at quarter end.
Q3 2023 total revenue of $165.8 million, including $140.0 million of license revenue tied to a one-time Neuraxpharm payment received in July 2023
BRIUMVI U.S. net sales of $25.1 million in Q3 2023, up from $0.1 million in Q3 2022
Q3 2023 net income of $113.9 million, or $0.80 per basic share, versus a net loss of $35.8 million in Q3 2022
Cash, cash equivalents and investment securities of $229.2 million as of September 30, 2023
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every TG Therapeutics filing is on SEC EDGAR ↗. 8-K briefs of other companies →